A team of researchers from the Sant Pau Research Institute (IR Sant Pau) has published a study in the Journal of ...

Under the terms of the agreement, TG Therapeutics obtains non-exclusive research, clinical and commercial rights to use MaxCyte’s Flow Electroporation ® technology and ExPERT™ platform. In return, ...

A Phase 2 clinical trial testing obexelimab in adults with relapsing types of multiple sclerosis is now recruiting ...

February 10-11: BIO CEO & Investor Conference 2025. Daniel Vitt, Ph.D., Chief Executive Officer of Immunic, will participate in one-on-one meetings at this conference, taking place in New York.

Multiple sclerosis (MS ... and about 2.9 million people worldwide. There are relapsing-remitting and progressive types of MS, but the course is rarely predictable. Researchers still don’t ...

Susie Wyss used to inject herself daily with a medication for multiple sclerosis. “The injection hurt. It caused welts, bruises, and sometimes permanent lipoatrophy,” Wyss told more than 800 people ...

Therapy with cladribine tablets was evaluated as a short-course regimen for RRMS in the Cladribine Tablets Treating Multiple Sclerosis Orally (CLARITY) study. [46–49] CLARITY was a Phase III ...

Relapsing-remitting multiple sclerosis is a type of multiple sclerosis ... MS is a chronic, progressive condition of the central nervous system (CNS) in which your immune system attacks myelin ...

Nov. 18, 2024 — Fampridine is currently used to improve walking ability in multiple sclerosis. A new study shows that it could also help individuals with reduced working memory, as seen in ...

relapsing remitting multiple sclerosis (RRMS), secondary progressive multiple sclerosis (SPMS), active systemic lupus erythematosus (SLE), focal segmental glomerulosclerosis (FSGS) and type 1 diabetes ...